-

Abintus Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Abintus Bio, Inc. (Abintus), a company pioneering first-in-class, off-the-shelf medicines that reprogram cells directly in vivo, today announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. Nicholas Boyle, Ph.D., Co-Founder, President and Chief Executive Officer, will present an overview of the company on January 13, 2022, at 10:00 am ET, and the presentation will be available to registered conference attendees.

Additionally, Abintus will be participating in a panel discussion organized by The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP) titled “Expanding the Possible with Next-Generation Cell Therapies.” The event will be held virtually on January 21, 2022, at 12:00 pm ET.

All inquiries: info@abintusbio.com

About Abintus Bio, Inc.

Driven by the founding vision of Empowering patients from within, Abintus is developing novel, off-the-shelf therapies that reprogram cells directly in vivo to improve patient outcomes and access. These therapies are based on the Abintus Modular Viral Platform (MVP) and have the potential to reprogram any cell type in the body and to target a range of diseases. The company’s initial In Vivo CAR-X products are designed to produce potent and durable immune responses against both hematologic malignancies and solid tumors. Abintus' initial funding syndicate included Takeda Ventures and The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP). Abintus Bio, Inc. (“Abintus”) is headquartered in San Diego. www.abintusbio.com.

Contacts

Nicholas Boyle
info@abintusbio.com

Abintus Bio, Inc.


Release Versions

Contacts

Nicholas Boyle
info@abintusbio.com

More News From Abintus Bio, Inc.

Abintus Bio Appoints Hebrew University Researcher Lior Nissim, Ph.D., As Head of Synthetic Biology and Concurrently Enters Agreement for Next-Generation, Synthetic Biology Technology to Enable In Vivo Genetic Medicines

SAN DIEGO--(BUSINESS WIRE)--Abintus Bio, Inc. (Abintus), a biotechnology company pioneering first-in-class, in vivo genetic medicines that engineer cells directly inside the body, today announced that Lior Nissim, Ph.D., has joined the company as Head of Synthetic Biology. In this role, Dr. Nissim will be responsible for leading Abintus’ synthetic biology program to enable the advancement of products with tunable, cell-type specific therapeutic gene expression. In connection with Dr. Nissim’s a...

Abintus Bio Enters Technology Agreement to Enhance In Vivo-Reprogrammed CAR Cell Potency and Durability Against Hematologic Malignancies and Solid Tumors

SAN DIEGO--(BUSINESS WIRE)--Abintus Bio, Inc. (Abintus), a company pioneering first-in-class, off-the-shelf medicines that reprogram cells directly in vivo, today announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center for the use of its next generation signaling technology (“1XX”) in Abintus’ In Vivo CAR-X products. These products have the potential to overcome the challenges of ex vivo CAR technologies and dramatically improve outcomes and access for patien...
Back to Newsroom